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Abstract In November 2008, the “2nd Summit on Osteopo-
rosis—Central and Eastern Europe (CEE)” was held in
Warsaw, Poland. Discussions at this meeting focused on the
identification and discussion of diagnostic, preventive, and
therapeuticmeasuresusedinCEE.Evaluatedinformationwas
used to identify issues regarding diagnosis and therapy of
osteoporosis in these countries to facilitate the subsequent
setup of appropriate support and development strategies. The
main debate was structured according to the following five
subjects: (1) present status and future perspectives for
implementation of FRAX® into local (CEE) diagnostic
algorithms, (2) principles of drug selection in osteoporosis
treatment in CEE countries, (3) nonpharmacological inter-
ventions in osteoporosis treatment and prophylaxis in CEE
countries, (4) treatment benefit evaluation, and (5) cost–
effectiveness and evaluation of reimbursement policies in
CEE countries. The most important and substantial comments
of the delegates are summarized in the present article. The
multinationalpanel ofexperts withrepresentativesfrommany
CEE countries as well as Austria and Switzerland made the
“2nd Summit on Osteoporosis—CEE” a perfect platform to
identify issues and needs regarding diagnosis and therapy of
osteoporosis as well as the cost–effectiveness of osteoporosis
management in CEE countries. The information gained will
serveasabasisforthedevelopmentofstrategiestoresolvethe
identified issues at the “3rd Summit on Osteoporosis—CEE”
in November 2009.
Keywords CentralandeasternEurope.FRAX®.Diagnosis
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Introduction
In Europe, USA, and Japan, about 75 million people suffer
from osteoporosis [1]. During their lifetime, up to 50% of
women and 30% of men will experience an osteoporosis-
related fracture [2]. Particularly in the case of hip fractures,
immediate hospitalization is required that is quite often
followed by a long and problematic recovery; in addition, a
substantial number of patients become permanently disabled
after such a fracture. This protracted course of the disease
means that not only the patients’ quality of life is considerably
impaired but also that the costs for acute therapies and
postoperative measures including rehabilitation are substantial.
Hence, osteoporosis is one of the most serious chronic
diseases that causes an enormous financial burden.
Because of their often serious consequences, prevention
of fractures is the main goal of osteoporosis therapy.
Prerequisite to achieve this goal is the identification of
patients at risk for fractures by adequate diagnostic
measures. Osteoporosis is characterized by low bone
mineral density (BMD) [3]. Based on this parameter,
guidelines for therapeutic interventions recommend assess-
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of fracture, however, is caused multifactorially, including
risk factors such as age, prior fragility fractures, a parental
history of hip fracture, smoking, use of systemic cortico-
steroids, excess alcohol intake, and rheumatoid arthritis [6,
7]. Therefore, BMD together with these factors should be
considered when the fracture risk of an individual patient is
evaluated [6, 7]. Recently, the computer-based tool for
fracture risk calculation (FRAX®, http://www.shef.ac.uk/
FRAX/) has been developed. The algorithm of this tool
takes this multifactorial approach into account. While rather
simple to use, FRAX® generates very reliable data on the
individual fracture risk. Based on such information,
physicians can then decide on the appropriate measures to
be taken to prevent fractures.
In clinical practice, however, the diagnostic and thera-
peutic challenges of osteoporosis therapy are not always
met. In fact, a substantial proportion of individuals at high
risk, who have already had at least one fragility fracture,
including hip fractures [8, 9], are neither appropriately
diagnosed nor treated for probable osteoporosis [10–12].
Simplifying the diagnostic procedure by such easy-to-use
tools as FRAX® might increase the diagnosis rate of
osteoporotic patients and support the timely administration
of the required treatments. This tool, however, is not yet
available in every country.
Therefore, the discussions at the “2nd Summit on
Osteoporosis—Central and Eastern Europe (CEE)” concen-
trated on the need for appropriate discrimination and
evaluation of the individual osteoporosis risk factors to
maximize the benefits of pharmacotherapy while limiting
the risks and costs that accompany treatment. Here, the
major aim was to identify and discuss diagnostic, preven-
tive, and therapeutic measures used in CEE. A comprehen-
sive analysis covering these aspects in all CEE countries is
not yet available, most probably because of considerable
differences between the individual countries not only
regarding culture, living conditions, life expectancy but
also regarding availability and use of medical treatment for
osteoporosis and, finally, reimbursement.
Representatives from Austria and Switzerland but mainly
from CEE countries including the Czech Republic, Hungary,
Poland, Romania, Slovakia, and Slovenia participated in the
“2nd summit on Osteoporosis—CEE”. This multinational
panel of experts made the meeting a perfect platform to
develop the above topics. Discussion was based on six
international reference publications [13–18]; the main debate
was structured according to the following five subjects:
1. Present status and future perspectives for implementa-
tion of FRAX® into local (CEE) diagnostic algorithms
2. Principles of drug selection in osteoporosis treatment in
CEE countries
3. Nonpharmacological interventions in osteoporosis
treatment and prophylaxis in CEE countries
4. Treatment benefit evaluation
5. Cost–effectiveness and evaluation of reimbursement
policies in CEE countries
The information evaluated during the summit was used
to identify issues regarding diagnosis and therapy of
osteoporosis in CEE countries to facilitate the subsequent
setup of appropriate support and development strategies.
The most important and substantial comments of the
delegates are summarized below.
Present status and future perspectives
for implementation of FRAX® into local (CEE)
diagnostic algorithms
The computer-based tool FRAX® has been developed by
the WHO from studying population-based cohorts from
Europe, North America, Asia, and Australia to evaluate the
fracture risk of patients (http://www.shef.ac.uk/FRAX/). It
is based on individual patient models that integrate the risks
associated with clinical risk factors as well as BMD at the
femoral neck. FRAX® represents a very sensitive tool to
identify patients with a high fracture risk; its output is a 10-
year probability of hip fracture and the 10-year probability
of a major osteoporotic fracture (clinical spine, forearm,
hip, or shoulder fracture). Use of FRAX® for fracture risk
calculation is recommended by current European guidelines
[15] as well as by guidelines of the National Osteoporosis
Foundation and the World Health Organization (WHO) [19]
to improve diagnosis, facilitate the decision for appropriate
therapeutic interventions, and, in the long run, save costs by
fracture prevention.
Prerequisite for the implementation of FRAX® in a
specific country is information on the local epidemiol-
ogy of fractures and death. In several countries
including UK, Germany, Sweden, Japan, the USA, and
others, sufficient reliable epidemiological data are
available to calculate the fracture risk of an individual
patient by FRAX®. In countries where such epidemio-
logical data are missing, the guidelines for the use of
FRAX® recommend to “use (the FRAX® model of) the
country for which the epidemiology of osteoporosis
most closely approximates your country.” (http://www.
shef.ac.uk/FRAX/). However, this approach is in a way
problematic because the incidence of hip fractures and
death differ considerably (10- to 15-fold) between
countries [20–22]. Hence, to obtain reliable information
on fracture risk by FRAX®, local data on fracture and
death rates should be assessed before implementation of
FRAX® in a specific country.
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Expectations from FRAX® in CEE countries The final aim
of any interventional procedure in osteoporosis is the
development of a uniform, diagnostic, therapeutic, and
cost–effective algorithm of treatment and fracture prevention.
FRAX® has been developed as a 10-year fracture risk
calculator based on femoral neck densitometry (or BMD)
and available independent clinical fracture risk factors.
FRAX® generally does not change WHO diagnostic
classification of osteoporosis; however, with its use, we
can expect that a lower number of younger patients at low
risk as well as a higher number of elderly patients at high
risk will be selected for treatment.
FRAX® can be a helpful screening tool in general
practitioner case-finding strategies to identify patients with
a high fracture risk (diagnostic threshold) without the use of
densitometry or with only limited access to densitometry.
Specific issues regarding the use of FRAX® in CEE
countries The audience agreed that presently, there are
insufficient, satisfactorily validated studies concerning
spine densitometry and fracture rates available in CEE that
can be utilized in the FRAX® algorithm.
Prior to the implementation of FRAX® into national
routine guidelines, reliable local fracture data need to be
assessed for each CEE country to enable appropriate risk
assessment and local cost–effectiveness calculation of the
whole procedure.
As a next step, the implementation of FRAX® software
in routine densitometry devices could be helpful in
everyday diagnostic procedures in CEE countries. Through
this, a consistent and reliable diagnosis of osteoporosis
could be guaranteed cross-nationally in CEE. Besides, the
effort for physicians would be minor because of the
straightforward methodical approach of FRAX®.
The following practical remarks and questions were raised
by the summit participants Is it possible that the history of
nontraumatic osteoporotic fractures as well as low lumbar
(beside hip) BMD values (T score of ≤2.5 standard
deviation) could define a more precise diagnostic threshold
with the aim of improving an interventional threshold for
pharmacological treatment? It was agreed that including
such fracture information will not yield better results.
In summary, all representatives of the CEE countries
expressed interest in the use of FRAX® for fracture risk
evaluation in osteoporotic patients. The discussion, howev-
er, made clear that currently, the FRAX® model cannot be
implemented in CEE countries because reliable fracture
data are not available to adjust the model to the special
circumstances in each individual CEE country. Since the
beginning of 2009, a FRAX® model based on Austrian
fracture data is available. The authors suggest that in
accordance with http://www.shef.ac.uk/FRAX, Austria
might be used as a surrogate country for CEE countries
until sufficient data for the establishment of a CEE-specific
FRAX® algorithm are available.
Principles of drug selection in osteoporosis treatment
in CEE countries
A range of drugs is available for the therapy of osteoporosis
that significantly reduces the risk of vertebral and non-
vertebral fractures [15, 19]. Most commonly used drugs are
selective estrogen receptor modulators such as raloxifene;
bisphosphonates such as alendronate, risedronate, ibandro-
nate, and zoledronate; parathyroid hormone (PTH)-derived
drugs such as teriparatide; and so-called dual action bone
agents (DABA) including strontium ranelate. In addition,
hormone replacement therapies (females, estrogen; males,
testosterone) can be used [15, 19].
The decision for one or more of these therapeutic
approaches is based primarily on the fracture risk of an
individual patient [4, 5] but also on biochemical markers
for bone turnover [6, 7]. In addition, individual patient’s
characteristics should be considered: Will the patients
comply with a therapy? Are they able to swallow their
medication or do they need intravenous application? How is
their individual tolerability to a certain drug? etc.
Comments of the delegates on drug selection in CEE countries
Treatment decisions in osteoporosis should be based on a
multifactorial approach Treatment decisions in osteoporo-
sis should be based on the absolute risk of fracture (when
possible by use of FRAX®) which combines the patient’s
clinical risk factors with BMD values. In all cases of low
bone mass or low-trauma fractures, metabolic disorders as
secondary causes of osteoporosis should be ruled out;
however, causative management of secondary osteoporosis
does not exclude the need for antifracture pharmacotherapy.
In selected patients, an assessment of bone turnover rates
using biochemical markers of bone turnover could possibly
influence the selection of the most appropriate treatment.
General considerations on drug selection Drug selection in
osteoporosis treatment should take into account the mech-
anism of action of the drug and the results of randomized,
placebo-controlled clinical trials demonstrating the effects
of a given intervention on fracture risk. Comorbidities as
well as nonskeletal risks and benefits of the drug should
also be considered.
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adherence (compliance and persistence) to the treatment is as
importantaseffectiveness.Thesuitabilityofthedrugforlong-
term administration and factors such as patient’sp r e f e r e n c e ,
tolerability, and convenience should be taken into account.
Anticatabolic drugs are most appropriate in patients with
high bone turnover, while anabolic drugs demonstrate
efficacy irrespective of bone turnover. Anabolic treatment
should be chosen particularly in patients with low bone
formation or extremely low bone mass, in elderly, in cases
of glucocorticoid-induced osteoporosis, or after multiple
fractures where preservation of bone mass and bone
architecture by antiresorptive drugs is not sufficient to
reduce the high absolute risk of fracture efficiently.
Recent studies give evidence that sequential treatment
with anabolic followed by anticatabolic drugs may preserve
and even improve the gain in bone mass needed for long-
term efficacy.
Bisphosphonates All bisphosphonates are highly effective
in postmenopausal female and male patients with estab-
lished osteoporosis, especially in those with high bone
turnover. Presently, there is no evidence of any effect of
bisphosphonates in osteopenia.
The main differences among various oral bisphospho-
nates relate mostly to compliance and persistence (adher-
ence to therapy). A once-a-month schedule is better
accepted by patients than once a week, which, in turn,
seems to be better than a daily schedule.
Intravenous bisphosphonates (ibandronate, 3 mg every
3 months; zoledronate, 5 mg once a year) may be
particularly useful in the treatment of patients with
gastrointestinal disorders and patients intolerant to oral
bisphosphonates, as well as patients who are chronically
immobilized (as a result of vertebral or hip fractures; stroke
patients), or with dementia. Once yearly zoledronic acid
therapy does not only maintain bone microarchitecture but
also enables sufficient bone preservation. Moreover, apart
from the bone-preserving effect, zoledronic acid adminis-
tered once a year guarantees high adherence to therapy.
Dual action bone agents Strontium ranelate, with its
synchronous antiresorptive and pro-anabolic effects, shows
antifracture efficacy in all types of osteoporotic fractures,
both vertebral and nonvertebral, regardless of initial BMD
or bone turnover. Moreover, a statistically significant
reduction in the incidence of femoral fractures in older
women with low bone mineral density can be shown.
Parathyroid hormone-derived drugs Teriparatide is a high-
ly effective bone anabolic agent; treatment studies show a
highly significant reduction of osteoporotic fractures of any
type in patients with severe osteoporosis. Presently, it is the
only medication which restores bone structure indepen-
dently of the degree of initial disarrangement. For safety
reasons,however,thedurationoftreatmenthasbeenrestricted
to 24 months. In order to maintain the achieved therapeutic
effects, continuation of treatment with bisphosphonates
should be considered.
In summary, drug selection should be based not only on
physical (absolute risk of fractures, biochemical markers of
bone turnover, etc.) but also on patient-specific (comorbid-
ities, patient’s preference, tolerability, ability to comply,
etc.) factors. In addition, the mode of action of a drug
should match the pathological characteristics (e.g., high/low
bone turnover) of an individual patient. Specifically,
anticatabolic drugs are most appropriate in patients with
high bone turnover, while anabolic drugs demonstrate
efficacy irrespective of bone turnover. To achieve long-
term efficacy, sequential treatment with anabolic followed
by anticatabolic drugs should be considered. All bisphosph-
onates are highly effective in postmenopausal patients with
established osteoporosis; decision on oral vs. intravenous
formulations as well as on the application schedule should
depend on patient characteristics. DABAs are suitable for
all types of fractures irrespective of BMD and bone
turnover. The PTH-derived drug teriparatide is currently
the only formulation which restores bone structure also in
patients suffering from severe osteoporosis.
Nonpharmacological interventions in osteoporosis
treatment and prophylaxis in CEE countries
Besides proper medication, a multitude of further meas-
ures have been demonstrated to reduce the risk of
osteoporosis, osteoporosis-related fractures, and fall-
related injuries. Physical activity, for example, has not
only a positive impact on bone mineral density [23–25]
but also prevents falls especially in elderly patients by
increasing their balance and physical confidence [26].
Adequate intake of calcium supports the positive effect of
physical activity [27] and increases bone mineral density
[28]. Regular intake of vitamin D reduces the risk of falls
and the fracture risk [29, 30].
Comments of the delegates on nonpharmacological
interventions and prophylaxis in CEE countries
Considerations regarding vitamin D supplementation Dur-
ing any osteoporosis therapy, vitamin D status should be
optimized (serum 25OHD >30 ng/ml in serum) for a proper
antifracture effect.
Preventions of falls and hip fracture risk reduction are
evidenced for vitamin D supplementation in vitamin D-
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D should range between 800-2,000 IU.
Patients with decreased renal function should be supple-
mented with activated vitamin D metabolites.
A history of kidney stones or hypercalciuria needs further
evaluation before initiating vitamin D supplementation.
Other considerations Many nonspinal fractures result from
a fall. Hence, each elderly patient should be asked about
falls; if one or more are reported, a multidisciplinary
program should be implemented.
General practitioners should provide printed educational
materials with information on prophylaxis such as fall
prevention, proper daily exercise, adequate lifestyle
changes, etc.
Spinal dysfunction and peripheral joint pain limiting
movement as well as weakening of muscles should be
considered as indications for rehabilitation.
Besides vitamin D intake, calcium supplementation is
the main approach used in fracture prevention and the
necessary complement to osteoporosis treatment. The
recommended daily dose of calcium is 500-1,500 mg.
In summary, besides calcium and vitamin D supplemen-
tation, the panel members underlined the importance of
comprehensively enquiring about the medical history of
patients, proper education as well as the use of multidisci-
plinary approaches in the prevention and treatment of
osteoporosis.
Treatment benefit evaluation in CEE countries
Monitoring the effects of osteoporosis therapy informs the
physician whether a certain treatment was efficient or not.
Besides fracture rates, several surrogate markers are
employed to evaluate the outcome of osteoporosis therapy.
The most commonly used surrogate markers are sequential
measurements of BMD and bone turnover markers (BTMs).
Stable or increasing BMD and suppressed BTMs are
associated with a reduction in fracture risk [31–34]. The
available surrogate measurements of bone strength which
are applied to assess the effects of osteoporosis treatment
were intensively discussed by the participants.
Comments of the delegates on treatment benefit evaluation
General considerations Presently, BMD measurements are
the most widely used and probably the best long-term
assessment of the efficacy of antifracture treatment. Bone
turnover can be monitored using BTMs (CTX, P1NP, OC).
However, the usefulness of these markers in the clinical
practice as a short-term (at 3 months) surrogate monitoring
tool in patients treated with antiresorptives (bisphospho-
nates, raloxifene, hormone therapy, calcitonin) or anabolic
(PTH) drugs needs to be further validated. In both BTMs
and BMD measurements, precision standards and quality
control by calculation of the least significant change (LSC)
for the biochemical assays and BMD measurements should
be taken into account for the interpretation of the individual
results. Only compliant patients may be defined as “nonre-
sponder” or “suboptimal responder” when no significant
changes (according to LSC) of BMD or BTMs are observed
during treatment. A patient is defined as compliant when
she/he correctly takes at least 80% of the prescribed doses of
the treatment in a minimal time interval of 1 year.
The most controversial point appeared to be the question
whether an incident fracture is a reliable clinical endpoint for
evaluation of a therapy’s effectiveness. Fractures do not
appear as uniform events being very heterogeneous depend-
ing on the analyzed country. On the one hand, a fracture is a
stochastic event (i.e., subject to randomness) that may or
may not occur in an osteoporotic patient regardless of the
treatment. On the other hand, fracture prevention is the
primary aim of osteoporosis treatment. However, the incident
fracture rate has been defined as the primary endpoint in all
relevant osteoporotic clinical trials but with potential limits
when judged in a single patient. It was agreed that an
incident fracture is not necessarily a treatment failure.
However, if the fracture occurs a considerable time after
the commencement of the treatment, the need for drug
change (anticatabolic to anabolic) and specific nonpharma-
cological intervention (fall prevention, balance training,
muscle strengthening) should be considered, if possible.
The general conclusion of all participants led to the
statement that treatment benefit evaluation can be consid-
ered one of the most important factors to improve long-term
antifracture efficacy. Since there are no direct tools for bone
strength measurement in living patients, we are presently
limited to existent surrogate ones.
Cost–effectiveness and evaluation of reimbursement
policies in CEE countries
As a chronic disease that in many cases is accompanied by
limiting complications and consequences, osteoporosis is a
very treatment- and, hence, cost-intensive condition. Con-
sidering also the high prevalence of this disease, the burden
imposed by osteoporosis on health care systems is
enormous. Especially in countries with limited resources
and health care budgets, the decision taken on diagnostic
and therapeutic measures to prevent or treat osteoporosis
has to be based not only on therapeutic but also on
economic considerations. Health-economy analyses that
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support the efficient allocation of such limited resources.
Indeed, economic evaluations have been performed to
compare distinct treatment strategies in osteoporosis [35–
37]. However, to realistically represent the cost/benefit of
these therapies in a certain area or country, detailed local
data on epidemiology, type of treatment, treatment
expenses, success rates, etc. have to be incorporated into
the evaluation.
Difficult and heterogeneous economic situation in CEE Due
to historical developments, the economic situation in CEE
countries shows large differences also regarding budgets
available for health care. Besides countries with sufficient
financial means for health care, there are also a consider-
able number of countries where resources are limited. Cost–
effectiveness analyses provide important information about
the value of different treatment options. Their outcome
assists decision makers who try to equitably allocate
constrained resources in order to achieve maximum health
care benefits. By definition, cost–effectiveness analyses
compare the costs and health effects of an intervention to
assess whether it is worth doing from an economical
perspective. From an ethical point of view, economically
dealing with resources is a must.
Data required for cost–effectiveness analyses are not
available With respect to osteoporosis and cost–
effectiveness, reliable epidemiological data and the exact
cost of osteoporosis and fracture treatments are neces-
sary as well as data on normal life expectancy and
gross national product. While in Poland, the cost–
effectiveness of alendronate and raloxifene (once a
day) as well as ibandronate (once a month) therapies
for postmenopausal osteoporosis were evidenced and
published [38], in most other CEE countries, the cost of
osteoporosis treatment is not available. One of the reasons
that should be considered in this context is that registers
for hip fractures and other fractures are far from being
satisfactory in this region.
Reimbursement strategies are very heterogeneous in distinct
CEE countries Only in some CEE countries do uniform
reimbursement criteria exist. In general, however, reim-
bursement of diagnostic procedures, prevention, and ther-
apy of osteoporosis varies considerably among countries as
well as factors influencing reimbursement policies. In fact,
there are currently no recommendations on how and to
what extent reimbursement policies in CEE countries
should be influenced by cost–effectiveness analyses. In
addition, in the majority of CEE countries, medical
communities are not involved in cost–effectiveness
evaluation.
Which substances are reimbursed in CEE In the majority
(>50%) of CEE countries, alendronate, risedronate, ibandr-
onate, zoledronic acid, strontium ranelate, and teriparatide/
rh PTH are reimbursed; however, while in some countries,
therapy costs are fully covered, in other countries, costs are
reimbursed only partially. Raloxifene is not reimbursed at
all in some countries.
Recommendations for the future In the long run, the main
approach should focus on (a) the development of CEE-
specific FRAX® algorithms to guarantee reliable diagnosis,
thereby increasing the efficacy of therapeutic measures, and
(b) country-specific cost–effectiveness models to facilitate
calculation of regional therapy costs. Such models of the
cost–effectiveness of antifracture therapies would enable
the assessment and comparison of different drugs (alendr-
onate, ibandronate, risedronate, raloxifene, strontium rane-
late, zoledronic acid), different screening strategies (BMD,
BTM, DXA), or patients of different ages and sex.
In summary, the CEE delegates pointed out the hetero-
geneous economic situations in CEE countries and empha-
sized that country-specific health-economy analyses are
required to shed light on the cost–effectiveness of local
osteoporosis therapies. However, the data required to
conduct such analyses (epidemiology data, exact costs of
therapies, etc.) are not available. In addition, reimbursement
strategies vary considerably between countries, making an
objective evaluation of local situations even more difficult.
As a future perspective, they suggested that diagnosis and
therapy of osteoporosis should be based on the concerted
use of CEE-specific FRAX® algorithms and local cost–
effectiveness data.
Overall summary and outlook
The major aim of the “2nd summit on Osteoporosis—CEE”
was to identify and discuss diagnostic, prophylactic, and
therapeutic measures used in CEE countries to prevent and
treat osteoporosis [39]. Based on such information, issues
concerning the management of osteoporosis in these
countries should then be identified to provide the basis for
the development of suitable support and development
strategies.
It was agreed that a proper diagnosis especially of the
patient’s fracture risk is the absolute prerequisite for the
decision on an adequate and successful therapy. To
facilitate a simple but reliable diagnose of the fracture risk,
all representatives of the CEE countries argued for the
implementation of the computer-based tool FRAX® for
fracture risk evaluation in CEE. For this, information on the
local epidemiology of fracture and death rates is required.
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countries in CEE. Therefore, the first step toward FRAX®
implementation would be to develop a strategy on how
such information can be collected most efficiently in CEE
countries. Until sufficient local epidemiology data for the
establishment of CEE-specific FRAX® algorithms are
available, the Austrian FRAX® model was proposed as a
surrogate model for CEE.
Drug selection should be based on physical parameters
(absolute risk of fractures, biochemical markers of bone
turnover, etc.) as well as on patient-specific factors
(comorbidities, patient’s preference, tolerability, ability to
comply, etc.). Such patient characteristics should also be
considered when deciding on the way of administration
(oral vs. intravenous) and the administration schedule (daily
up to once a year). The most commonly used therapies are
bisphosphonates, DABA, and PTH-derived formulations.
In addition to such medication-based treatments, calcium
and vitamin D supplementation were discussed to be vital
for a successful therapy as well as measures such as
comprehensively enquiring about the patient’s medical
history, proper education, and, in general, the use of
multidisciplinary therapeutic approaches. For evaluation of
the benefit of a specific osteoporosis treatment, no direct
tools are currently available; therefore, surrogate ones have
to be employed.
Finally, the CEE delegates described the very heteroge-
neous economic situations in the different CEE countries
and emphasized that country-specific health-economy anal-
yses would be required to shed light on the cost–
effectiveness of local osteoporosis therapies. For such
studies, however, epidemiology data, data on the exact
costs of therapies, etc. have first to be evaluated in each
country. As soon as available, the combined use of CEE-
specific FRAX® algorithms and local cost–effectiveness
data would then allow an adequate and economical
management of osteoporosis.
In conclusion, the lively discussion and exchange of
information at the “2nd Summit on Osteoporosis—CEE” in
November 2008 made clear that this meeting is a very
helpful and authentic platform to identify issues and needs
regarding the diagnosis and therapy of osteoporosis as well
as the cost–effectiveness of osteoporosis management in
CEE countries. Based on the information gained, the “3rd
Summit on Osteoporosis—CEE” in November 2009 will
then focus on the development of answers and strategies to
resolve the identified issues.
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